PMC4408939_01
Effect of canakinumab on thermal curves and its impact on VAS.. Notes: (A) Thermal curves of the week preceding (red line) and the week following the administration of the first dose of canakinumab (blue line). (B) VAS values of the week preceding (red line) and the week following the administration of the first dose of canakinumab (blue line).. Abbreviation: VAS, visual analog scale.
dddt-9-1983Fig1.jpg
PMC4408939_01_dddt-9-1983Fig1.jpg
f1-dddt-9-1983
FMF. Figure 1 shows the profiles of body temperature and visual analog scale.
Effects of canakinumab on HRQoL and HAQ.. Notes: (A) Results of questionnaires on quality of life in relation to physical and mental health. (B) Results of questionnaires on quality of life in relation to physical health, filled in during the course of follow-up. (C) Results of questionnaires on quality of life in relation to mental health. (D) Results of questionnaires on the degree of disability in carrying out common daily activities.. Abbreviations: PCS, physical-component summary; MCS, mental-component summary; PF, physical functioning; RP, role limitations - physical; BP, bodily pain; GH, general health perception; VT, vitality; SF, social functioning; RE, role limitations - emotional; MH, mental health; Mth, month; HRQoL, health-related quality of life; HAQ, Health Assessment Questionnaire.
dddt-9-1983Fig2.jpg
PMC4408939_01_dddt-9-1983Fig2.jpg
f2-dddt-9-1983
Notably, the SF-36 MCS score at the end of the study exceeded that of the general population (Figure 2A). At baseline, scores for all SF-36 individual domains were lower than in the general population, especially for physical functioning, pain, and general health (Figure 2B). Further improvements were observed over the entire period of monitoring, with mean scores approaching normal (Figure 2B). The greatest improvements in mental functions were seen in vitality and social functioning (Figure 2C).